BioSpace News Archive

Rocket Pharmaceuticals, Inc. announces that patient dosing has commenced in the open-label, Phase 1 clinical trial of RP-A501, the Company’s adeno-associated viral vector-based gene therapy for the treatment of Danon disease.

Intact Vascular’s Tack Endovascular System® is highlighted as a treatment option for post-PTA dissections

Company encouraged by interim 13-week data in trial designed to assess the safety and tolerability of IMR-687 and explore the potential efficacy of IMR-687 on clinical outcome measures relevant to sickle cell disease

Cellular Biomedicine Group Inc. announced that several of its executives will participate in the upcoming CAR-TCR Summit Asia to be held in Shanghai, June 19-20, 2019.

ANI Pharmaceuticals, Inc. announced that it has acquired a pipeline of seven development stage generic products from Coeptis Pharmaceuticals, Inc.

Torque is currently conducting a Phase 1/2 clinical trial of TRQ-1501 for this indication.

Regional non-profit health plan expecting biggest turnout in history as employees volunteer at dozens of nonprofits in Massachusetts, New Hampshire, Rhode Island and Connecticut [18-June-2019] WATERTOWN, Mass. , June 18, 2019 /PRNewswire/ -- More than 1,000 Tufts Health Plan employees are traveling across New England today to serve local nonprofits as part of its 11

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this Summer to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research.

VANFLYTA® (quizartinib) is a FLT3 inhibitor MHLW-approved based on a survival benefit compared to salvage chemotherapy in adult patients with relapsed/refractory FLT3-ITD AML

Patients suffering from fibromyalgia experience significant improvement in pain, sleep, and depression symptoms after treatment with Tikun Olam medical cannabis, a new study published in the Journal of Clinical Medicine confirms.